From: Role of the CASZ1 transcription factor in tissue development and disease
 | Disease types | Gene expression/mutation | Proposed mechanism | Refs. |
---|---|---|---|---|
Cancers | Neuroblastoma | Down | Â | Â |
Hepatocellular carcinoma | Down | Regulates the MAPK/ERK pathway and MMP2/MMP9 expression, inhibiting abnormal tumor cell proliferation | [74] | |
Colorectal cancer Esophageal cancer Lung adenocarcinoma Clear cell renal cell carcinoma | Down | A new prognostic indicator | ||
Embryonal rhabdomyosarcoma | Down | RAS-MEK signaling or genetic alterations | [76] | |
Glioma | Up | Regulates target gene p75NTR transcription | [20] | |
Epithelial ovarian cancer | Up | Promotes the epithelial–mesenchymal transition of EOC cells | [21] | |
Lung adenocarcinoma | Up | Promotes cell migration and invasion by driving ITGAV expression | [78] | |
Other diseases | Ventricular septal defects (VSD) | Missense mutation p. L38p | – | [22] |
Dilated cardiomyopathy (DCM) | Nonsense mutation p.K351X and c.3781del (p.(Trp1261GlyfsTer29)) frameshift mutation | |||
Left ventricular noncompaction cardiomyopathy (LVNC) | p.Val815Profs*14 heterozygous frameshift variant | [24] | ||
Hypertension | Unknown | Interacts with MR and the Mi-2/NuRD complex to inhibit ENaCα and SGK expression | ||
Osteoarthritis | Unknown | Inhibits chondrocyte apoptosis and inflammatory response | [27] | |
Immune inflammation | Unknown | Orchestrates T helper (Th) cell differentiation | [87] | |
 | Fasting plasma glucose (FPG) | DNA methylation variants | – | [88] |
 | Stroke | CASZ1 genetic variants (rs4845941 and rs778228) | – | [90] |